Fibroblast growth factor 21 enhances cholesterol efflux in THP‑1 macrophage‑derived foam cells

Shang,Wei; Yu,Xuejing; Wang,Honglian; Chen,Tielin; Fang,Ying; Yang,Xianggui; Zhou,Puhui; Nie,Fang; Zhou,Qin; Zhou,Jianzhong

doi:10.3892/mmr.2014.2731

Fibroblast growth factor 21 enhances cholesterol efflux in THP‑1 macrophage‑derived foam cells

Authors:
- Wei Shang
- Xuejing Yu
- Honglian Wang
- Tielin Chen
- Ying Fang
- Xianggui Yang
- Puhui Zhou
- Fang Nie
- Qin Zhou
- Jianzhong Zhou
View Affiliations

Affiliations: Department of Cardiology, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, P.R. China, Core Facility of Genetically Engineered Mice, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, The Division of Molecular Nephrology, The College of Laboratory Medicine, Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: October 21, 2014 https://doi.org/10.3892/mmr.2014.2731
Pages: 503-508

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fibroblast growth factor 21 (FGF21) is a novel metabolic regulator. The present study aimed to investigate the effect of FGF21 on cholesterol efflux and the expression of ATP binding cassette (ABC) A1 and G1 in human THP‑1 macrophage‑derived foam cells. Furthermore, the present study aimed to investigate the role of the liver X receptor (LXR) α in this process. A model of oxidized low‑density lipoprotein‑induced foam cells from human THP‑1 cells was established. The effect of FGF21 on cholesterol efflux was analyzed using a liquid scintillation counter. The expression of ABCA1 and ABCG1 was determined using quantitative polymerase chain reaction and western blot analyses. FGF21 was found to enhance apolipoprotein A1‑ and high‑density lipoprotein‑mediated cholesterol efflux. FGF21 was also observed to increase the mRNA and protein expression of ABCA1 and ABCG1. Furthermore, LXRα‑short interfering RNA attenuated the stimulatory effects induced by FGF21. These findings suggest that FGF21 may have a protective effect against atherosclerosis by enhancing cholesterol efﬂux through the induction of LXRα‑dependent ABCA1 and ABCG1 expression.

View Figures

View References

1	Lusis AJ: Atherosclerosis. Nature. 407:233–241. 2000. View Article : Google Scholar : PubMed/NCBI
2	Maxfield FR and Tabas I: Role of cholesterol and lipid organization in disease. Nature. 438:612–621. 2005. View Article : Google Scholar : PubMed/NCBI
3	Rader DJ, Alexander ET, Weibel GL, Billheimer J and Rothblat GH: The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 50(Suppl): S189–194. 2009. View Article : Google Scholar : PubMed/NCBI
4	Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, Kontush A, Krauss RM, Otvos JD, Remaley AT and Schaefer EJ: HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem. 57:392–410. 2011. View Article : Google Scholar
5	Lewis GF and Rader DJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 96:1221–1232. 2005. View Article : Google Scholar : PubMed/NCBI
6	Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, et al: Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. 125:1905–1919. 2012. View Article : Google Scholar : PubMed/NCBI
7	Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, et al: Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 364:127–135. 2011. View Article : Google Scholar : PubMed/NCBI
8	Yu XH, Fu YC, Zhang DW, Yin K and Tang CK: Foam cells in atherosclerosis. Clin Chim Acta. 424:245–252. 2013. View Article : Google Scholar : PubMed/NCBI
9	Hu YW, Wang Q, Ma X, Li XX, Liu XH, Xiao J, Liao DF, Xiang J and Tang CK: TGF-beta1 up-regulates expression of ABCA1, ABCG1 and SR-BI through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells. J Atheroscler Thromb. 17:493–502. 2010. View Article : Google Scholar : PubMed/NCBI
10	Ni ZL, Zhao SP and Wu Z: ABCG1 - a potential therapeutic target for atherosclerosis. Med Hypotheses. 69:214–217. 2007. View Article : Google Scholar : PubMed/NCBI
11	Zhao C and Dahlman-Wright K: Liver X receptor in cholesterol metabolism. J Endocrinol. 204:233–240. 2010. View Article : Google Scholar : PubMed/NCBI
12	Tang SL, Chen WJ, Yin K, Zhao GJ, Mo ZC, Lv YC, Ouyang XP, Yu XH, Kuang HJ, Jiang ZS, et al: PAPP-A negatively regulates ABCA1, ABCG1 and SR-B1 expression by inhibiting LXRα through the IGF-I-mediated signaling pathway. Atherosclerosis. 222:344–354. 2012.PubMed/NCBI
13	Woo YC, Xu A, Wang Y and Lam KS: Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin Endocrinol (Oxf). 78:489–496. 2013. View Article : Google Scholar : PubMed/NCBI
14	Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, et al: FGF-21 as a novel metabolic regulator. J Clin Invest. 115:1627–1635. 2005. View Article : Google Scholar : PubMed/NCBI
15	Wente W, Efanov AM, Brenner M, Kharitonenkov A, Köster A, Sandusky GE, Sewing S, Treinies I, Zitzer H and Gromada J: Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes. 55:2470–2478. 2006. View Article : Google Scholar : PubMed/NCBI
16	Xu J, Stanislaus S, Chinookoswong N, Lau YY, Hager T, Patel J, Ge H, Weiszmann J, Lu SC, Graham M, et al: Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models - association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab. 297:E1105–E1114. 2009. View Article : Google Scholar
17	Hotta Y, Nakamura H, Konishi M, Murata Y, Takagi H, Matsumura S, Inoue K, Fushiki T and Itoh N: Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology. 150:4625–4633. 2009. View Article : Google Scholar : PubMed/NCBI
18	Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ and Kliewer SA: Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab. 8:77–83. 2008. View Article : Google Scholar : PubMed/NCBI
19	Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE and Kharitonenkov A: Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 149:6018–6027. 2008. View Article : Google Scholar : PubMed/NCBI
20	Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB and Etgen GJ: The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology. 148:774–781. 2007. View Article : Google Scholar : PubMed/NCBI
21	Ma AZ, Zhang Q and Song ZY: TNFa alter cholesterol metabolism in human macrophages via PKC-θ-dependent pathway. BMC Biochem. 14:202013.PubMed/NCBI
22	Chen SG, Xiao J, Liu XH, Liu MM, Mo ZC, Yin K, Zhao GJ, Jiang J, Cui LB, Tan CZ, et al: Ibrolipim increases ABCA1/G1 expression by the LXRα signaling pathway in THP-1 macrophage-derived foam cells. Acta Pharmacol Sin. 31:1343–1349. 2010.
23	Yan JQ, Tan CZ, Wu JH, Zhang DC, Chen JL, Zeng BY, Jiang YP, Nie J, Liu W, Liu Q, et al: Neopterin negatively regulates expression of ABCA1 and ABCG1 by the LXRα signaling pathway in THP-1 macrophage-derived foam cells. Mol Cell Biochem. 379:123–131. 2013.PubMed/NCBI
24	Jessup W, Gelissen IC, Gaus K and Kritharides L: Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr Opin Lipidol. 17:247–257. 2006. View Article : Google Scholar : PubMed/NCBI
25	Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D and Patsch W: Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 104:1108–1113. 2001. View Article : Google Scholar
26	Gordon DJ and Rifkind BM: High-density lipoprotein - the clinical implications of recent studies. N Engl J Med. 321:1311–1316. 1989. View Article : Google Scholar : PubMed/NCBI
27	Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J and Banach M: Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res. 51:314–324. 2012. View Article : Google Scholar : PubMed/NCBI
28	Meurs I, Van Eck M and Van Berkel TJ: High-density lipoprotein: key molecule in cholesterol efflux and the prevention of atherosclerosis. Curr Pharm Des. 16:1445–1467. 2010. View Article : Google Scholar : PubMed/NCBI